Explore
our Featured Trials

Filter
Country
Therapeutic Areas
Trial / Investigated Product Type
Healthy Volunteers
Trial Phase
Sorting:
NCT03767075
Recruiting
Other Drugs
Targeted Therapy
Monoclonal Antibody
Checkpoint Inhibitors
Diagnostic Test
+2

A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (BoB)

NCT03838042
Recruiting
Other Drugs
Targeted Therapy
Monoclonal Antibody
Checkpoint Inhibitors
Diagnostic Test
+2

INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies

NCT04625907
Recruiting
Chemotherapy
Radiation Therapy
Other Drugs
Targeted Therapy
Diagnostic Test
+2

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma (FaR-RMS)

NCT01356290
Recruiting
Chemotherapy
Other Drugs
Targeted Therapy
Monoclonal Antibody
Combination Product
+2

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors (MEMMAT)

NCT03970447
Recruiting
Chemotherapy
Radiation Therapy
Other Drugs
Targeted Therapy
Diagnostic Test
+2

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)

NCT04031677
Recruiting
Chemotherapy
Procedure
Other Drugs

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma (STRASS2)

NCT03678025
Recruiting
Chemotherapy
Other Drugs
Hormone Therapy

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

NCT03903835
Recruiting
Chemotherapy
Other Drugs
Targeted Therapy
Hormone Therapy
Diagnostic Test
+2

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer (ProBio)

NCT04111978
Recruiting
Other Drugs
Hormone Therapy

MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)

NCT04205552
Recruiting
Monoclonal Antibody
Checkpoint Inhibitors

Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients (NEOpredict)